Compare FTFT & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTFT | GTBP |
|---|---|---|
| Founded | N/A | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 8.5M |
| IPO Year | 2008 | 2016 |
| Metric | FTFT | GTBP |
|---|---|---|
| Price | $1.63 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,158,125.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $0.40 |
| 52 Week High | $4.03 | $3.73 |
| Indicator | FTFT | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 37.31 |
| Support Level | $1.42 | $0.42 |
| Resistance Level | $1.74 | $0.59 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 35.08 | 27.15 |
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.